Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00170950 · ClinicalTrials.gov registry record · Phase 3
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
A Phase 3 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 11,506
- Enrollment target
NCT00170950 is a Phase 3 study that was terminated before completion, run by Novartis. The registered enrollment target is 11,506 participants.
The verdict
NCT00170950, a Phase 3 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 11,506 participants
- Enrollment target
Study Summary
A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.
Interventions
- DRUG Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1
- DRUG Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2
- DRUG Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
- DRUG Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1
- DRUG Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,506 participants |
| Start Date | 2003-10 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00170950
The ClinicalTrials.gov registry entry for NCT00170950 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 11,506 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1 is the first listed.
NCT00170950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00170950 about?
NCT00170950 is a clinical study titled "Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension". A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.
What is the current status of trial NCT00170950?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 11,506 participants. The study started on 2003-10. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00170950?
The interventions under investigation include: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1 (DRUG), Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 (DRUG), Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter (DRUG), Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1 (DRUG), Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2 (DRUG).
Who is sponsoring clinical trial NCT00170950?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.